oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2

Summary

oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2 (MONDO:0956996) is a disease. A subtype of IDH-mutant and 1p/19q-codeleted oligodendroglioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2
Mondo ID	MONDO:0956996
DOID	DOID:0081281
GARD	0026783
Is cancer (heuristic)	no

Disease family

This is a subtype of IDH-mutant and 1p/19q-codeleted oligodendroglioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › malignant glioma › oligodendroglial tumor › anaplastic oligodendroglioma › IDH-mutant and 1p/19q-codeleted oligodendroglioma › oligodendroglioma, IDH-mutant and 1p/19q-codeleted grade 2

Related subtypes (1): oligodendroglioma, IDH-mutant and 1p/19q-codeleted, grade 3

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.